Chronic Myelogenous Leukemia (ASC4MORE)
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
|This study is recruiting: Phase II||Actual Start Date: [November 22, 2018]||Estimated Completion Date: [October 20, 2021]||Novartis Reference Number: CABL001E2201|
|Condition: Chronic Myelogenous Leukemia in Chronic Phase||Interventions: asciminib, nilotinib, imatinib||Estimated Enrollment: [120 participants]||ClinicalTrials.gov Identifier: NCT03578367|
|This study is recruiting: Phase II||Actual Start Date: [November 22, 2018]|
|Estimated Completion Date: [October 20, 2021]||Novartis Reference Number: CABL001E2201|
|Condition: Chronic Myelogenous Leukemia in Chronic Phase||Interventions: asciminib, nilotinib, imatinib|
|Estimated Enrollment: [80 participants]||ClinicalTrials.gov Identifier: NCT03578367|
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP).
Participants may be eligible to participate if they:
- Are 18 years or older
- Have Confirmed diagnosis of CML-CP
- Have Minimum of 2 years treatment with imatinib first line for CML-CP
- BCR-ABL1 ratio ≥ 0.01% IS and ≤ 1% IS at the time of study entry
- Must not have achieved deep molecular response (MR4) at any time during prior imatinib therapy
- Meet other eligibility criteria
Find a Trial Site Location
To find a list of all our recruiting site locations, enter your address below.
Still Have a Question?
Are you a Patient or Caregiver looking for more information?
Are you a Health Care Professional looking for more information?
To view eligibility requirements for this trial, arms and interventions, trial sites and study design, please click to visit this trial on www.clinicaltrials.gov.
Other chronic myelogenous leukemia trials you might be interested in:
A Phase III, Multicenter, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors.
BCR-ABL1 - Breakpoint cluster region-Abelson murine leukemia, CML-CP - Chronic Myelogenous Leukemia in Chronic Phase
Last Updated: May 1, 2019